BridgeBio to Report Phase 3 Results for Small Molecule BBP-418 in LGMD2I/R9 FORTIFY Study, along with Third Quarter 2025 Financial Results Next Week

Group 1 - BridgeBio Pharma, Inc. is a biopharmaceutical company focused on discovering and delivering medicines for genetic diseases, with a pipeline that includes early science to advanced clinical trials [2] - The company will host two business update calls to provide insights into its operations and developments [1] - The FORTIFY Phase 3 Interim Analysis for Limb-girdle Muscular Dystrophy Type 2I/R9 will be presented in a webinar on October 27, 2025 [3] Group 2 - The Q3 2025 earnings report is scheduled for October 29, 2025, at 4:30 pm ET [3] - BridgeBio was founded in 2015 and aims to apply advances in genetic medicine to benefit patients quickly [2]